AI-generated summary
The authors conducted a prospective randomized controlled trial of 650-nm low-level laser therapy in 50 patients with overactive bladder, measuring nitric oxide and urinary nerve growth factor before and after treatment. They report significant changes in both markers after the intervention and suggest they may serve as biomarkers of treatment response. The abstract does not report the size or direction of these changes in detail.
- Participants
- 50
- Who or what was studied
- Patients with overactive bladder
- Wavelengths
- 650 nm
- Limits stated in the abstract
- The abstract does not report the magnitude of marker changes, the comparator arm results, or long-term follow-up, and the biomarker claims require further research.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
To investigate the potential of nitric oxide (NO) and urinary nerve growth factor (NGF) as indicators of therapeutic outcomes in overactive bladder (OAB) patients undergoing low-level laser therapy (LLLT) via a prospective randomized controlled trial. Fifty OAB patients participated in the study and were subjected to LLLT using 650-nm laser irradiation. The study employed a prospective randomized controlled trial design. Nitric oxide and urine NGF levels were assessed before and after the LLLT intervention to evaluate their correlation with therapeutic outcomes. The study provided evidence supporting the effectiveness of LLLT as a treatment modality for OAB. Analysis of NO and urine NGF levels revealed significant changes following LLLT intervention suggesting their potential as biomarkers for assessing therapeutic response in OAB patients. These biomarkers hold promise for aiding clinicians in evaluating treatment response and personalizing therapy approaches for OAB patients. This study highlights the utility of LLLT in managing OAB and underscores the importance of exploring biomarkers such as nitric oxide and urinary nerve growth factor to enhance treatment efficacy assessment. The findings suggest that NO and urine NGF levels may serve as valuable indicators of therapeutic outcomes in OAB patients undergoing LLLT. Further research is warranted to elucidate the underlying mechanisms and optimize the clinical application of LLLT in OAB management.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Nitric oxide, Laser, Randomized controlled trial. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.